We read with great interest the article by Mahmoudian et al., who evaluated soluble triggering receptor expressed on myeloid cells 2 (sTREM2) as a non-invasive biomarker for early metabolic dysfunction-associated steatohepatitis (MASH) in women with metabolic dysfunction-associated steatotic liver disease (MASLD) [1]. By combining plasma sTREM2 measurements with hepatic TREM2 mRNA expression, CD68+ macrophage counts and detailed histology, the authors offer a carefully phenotyped description of early MASH in a bariatric surgery cohort.
